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Abstract. 
 
The plasminogen (Plg)/plasminogen activa-
tor (PA) system plays a key role in cancer progression,
presumably via mediating extracellular matrix degrada-
tion and tumor cell migration. Consequently, uroki-
nase-type PA (uPA)/plasmin antagonists are currently
being developed for suppression of tumor growth and
angiogenesis. Paradoxically, however, high levels of PA
inhibitor 1 (PAI-1) are predictive of a poor prognosis
for survival of patients with cancer. We demonstrated
previously that PAI-1 promoted tumor angiogenesis,
but by an unresolved mechanism. We anticipated that
PAI-1 facilitated endothelial cell migration via its
known interaction with vitronectin (VN) and integrins.
However, using adenoviral gene transfer of PAI-1 mu-
tants, we observed that PAI-1 promoted tumor angio-
genesis, not by interacting with VN, but rather by in-
hibiting proteolytic activity, suggesting that excessive
plasmin proteolysis prevents assembly of tumor vessels.
Single deﬁciency of uPA, tissue-type PA (tPA), uPA re-
ceptor, or VN, as well as combined deﬁciencies of uPA
and tPA did not impair tumor angiogenesis, whereas
lack of Plg reduced it. Overall, these data indicate that
plasmin proteolysis, even though essential, must be
tightly controlled during tumor angiogenesis, probably
 
to allow vessel stabilization and maturation. These data
provide insights into the clinical paradox whereby PAI-1
promotes tumor progression and warrant against the
uncontrolled use of uPA/plasmin antagonists as tumor
angiogenesis inhibitors.
Key words: angiogenesis • tumor invasion • proteolysis
• migration • serine protease
 
Introduction
 
Tumor progression involves the disruption of anatomical
barriers and penetration of tumor cells into normal adjacent
host tissues, as well as the infiltration of normal host cells
into the tumor. Such migratory and tissue remodeling
events are, among others, regulated by different proteolytic
 
systems. Among the
 
 
 
proteases that play an active role in
these processes are the serine proteases of the plasminogen
 
(Plg)
 
1
 
/plasminogen activator (PA) system (Andreasen et
al., 1997). Urokinase-type (uPAs) and tissue-type plasmino-
gen activators (tPAs) both activate the zymogen Plg into its
active form, plasmin. uPA is secreted as an inactive pre-
cursor (pro-uPA) that binds with high affinity to a specific
cell surface glycosylphosphatidylinositol-anchored receptor
(the uPA receptor [uPAR]). Concomitant binding of pro-
uPA to uPAR and Plg to nonspecific binding sites at the cell
surface strongly enhances plasmin generation.
It is generally believed that uPA at the cell surface ini-
tiates a proteinase cascade, which in turn leads to break-
down of the extracellular matrix and thereby promotes
cellular migration. This conclusion is supported by the fact
that uPA and uPAR are highly expressed by tumor cells
or by surrounding stromal cells, and that they are both in-
dependent prognostic indicators in human cancer (Dano
et al., 1994; Reuning et al., 1998; Stephens et al., 1999). In
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addition, the use of antisense mRNA for uPA and uPAR,
of natural or synthetic serine protease inhibitors, or of
uPAR antagonists, all reduced tumor invasion (Min et al.,
1996; Carmeliet and Collen, 1998). Consequently, uPA/
uPAR/plasmin antagonists are currently being developed
as therapeutic strategies to inhibit tumor angiogenesis and
progression.
PA inhibitor 1 (PAI-1) is the primary physiological in-
hibitor of uPA and tPA. It not only
 
 
 
regulates the pro-
teolytic
 
 
 
activity of uPA, but also determines
 
 
 
the level of
uPA bound to uPAR by promoting the rapid endocytosis
of the trimolecular uPA–PAI-1–uPAR complex (Conese
and Blasi, 1995; Blasi, 1997). However, it has also been
implicated in modulating cell migration via alternative
mechanisms (Deng et al., 1996; Stefansson and Lawrence,
1996; Blasi, 1997; Loskutoff et al., 1999), even though con-
clusive in vivo evidence is lacking. By blocking the inter-
action between vitronectin (VN), uPAR, and integrins,
PAI-1 may induce cell detachment from the extracellular
matrix and thereby promote cellular migration and tumor
invasion. However, the relevance of the latter mechanism
in overall tumor growth and angiogenesis has not been
confirmed in vivo.
Surprisingly high, rather than low, levels of PAI-1 are
predictive of poor survival prognosis for patients suffer-
ing from a variety of different cancers (Pedersen et al.,
1994a,b). To date, the molecular mechanisms of this appar-
ent paradox remain largely unexplained, raising concerns
about whether therapeutic strategies to suppress tumor
growth and angiogenesis should be aimed at inhibiting or
increasing uPA/plasmin proteolysis. These questions have
been difficult to address, largely because uPA promotes,
and PAI-1 suppresses, tumor growth in most available ex-
perimental tumor models. However, recently PAI-1 was
 
found to promote tumor growth and angiogenesis (Bajou
et al., 1998) in a highly reproducible mouse tumor model.
The availability of this model now allows us to examine the
molecular mechanism by which PAI-1 promotes tumor an-
giogenesis (i.e., either by inhibiting the proteolytic activity
or by interrupting the interaction between VN and uPAR
or integrins). To address this question and to further deter-
mine the respective role of the different members of the
Plg/plasmin system, we have transplanted malignant kerati-
nocytes into wild-type (WT) mice and mice lacking uPA,
tPA, uPA and tPA, uPAR, Plg, PAI-1, or VN. We also per-
formed adenoviral gene transfer experiments using PAI-1
mutants that selectively inhibit PA activity or no longer
bind to VN. We provide direct evidence that plasmin is in-
volved in the formation of new vessels by host endothelial
cells, but that PAI-1 control of proteolytic breakdown is re-
quired. These data not only help to explain the apparent
paradox that high levels of a proteinase inhibitor promote
tumor angiogenesis and are positively correlated with tu-
mor progression in patients, but also warrant against the
uncontrolled use of uPA/plasmin inhibitors for suppression
of tumor angiogenesis.
 
 
 
Furthermore, they indicate that
neutralization of PAI-1 may be an attractive new target for
antiangiogenic therapy
 
Materials and Methods
 
Mice
 
Homozygous mice with single (uPA
 
2/2
 
, tPA
 
2/2
 
, uPAR
 
2/2
 
, and VN
 
2/2
 
mice) or combined deficiencies (tPA
 
2/2
 
/uPA
 
2/2
 
 mice) and their corre-
sponding WT with a mixed genetic background of 75% C57BL/6 and 25%
129 SV/SL strain were generated as described previously (Carmeliet et al.,
1994; Zheng et al., 1995; Carmeliet and Collen, 1998). Tumor angiogenesis
and invasion in PAI-1
 
2/2 
 
(Carmeliet et al., 1993a,b) and WT mice were
evaluated in three different sets of experiments using mice with different
genetic background obtained by two, three, or four backcrosses with
C57BL/6 strain. In each set of experiments, similar results were obtained
and therefore the data presented in Table I were pooled. The Plg
 
2/2
 
 mice
were derived from those generated previously (Bugge et al., 1995; Ploplis
et al., 1998). They have been backcrossed 1 or 11 times with C57BL/6
strain, yielding similar results in two different sets of experiments pre-
sented in Table I. Mice of either sex used for experiments were littermate
mice, produced by mating of heterozygous brothers and sisters between 8
and 12 wk old. Genotypes of mice were established using tail biopsy DNA
preparation by either Southern blot analysis or PCR assays (Carmeliet et
al., 1993b, 1994; Bugge et al., 1995).
 
Cell Culture
 
Malignant murine keratinocytes (PDVA cells; Fusenig et al., 1978) were
routinely grown in DME containing a fourfold concentration of amino ac-
ids and vitamins (GIBCO BRL), 10% FCS (GIBCO BRL), and antibiot-
ics in a humidified incubator at 37
 
8
 
C, 5% CO
 
2
 
. Cells (2 
 
3
 
 10
 
5
 
) were plated
on collagen gel (4 mg/ml of type I collagen isolated from rat tail tendons)
inserted in teflon rings (Renner GmbH) and maintained in culture for 1 d
before transplantation into mice as described previously (Fusenig et al.,
1983; Bajou et al., 1998). For transplantation assays in VN
 
2/2
 
 mice, kerati-
nocytes were precultured on the collagen gels in the presence of 10% se-
rum derived from VN
 
2/2
 
 mice.
 
Transplantation Assay in Mice
 
The cell-coated collagen gels were covered with a silicone transplantation
chamber (Renner GmbH) and implanted in toto onto the dorsal muscle
fascia of mice as described previously (Skobe et al., 1997; Bajou et al.,
1998). 2 wk later, transplants were resected, embedded in Tissue Tek
(Miles Laboratories, Inc.), and either frozen in liquid nitrogen for cryostat
sectioning or embedded in paraffin after zinc formalin fixation.
 
Table I. Tumor Angiogenesis and Invasion in WT, PAI-1
 
2/2
 
, 
and Plg
 
2/2
 
 Mice Injected or Not with WT or Mutated
hPAI-1 Adenovirus
 
Genotype Virus Mice
Plasma level
of hPAI-1 Angiogenesis Invasion
 
n ng/ml
 
WT AdRR5 control 11
 
,
 
0.8
 
111 111
 
PAI-1
 
2/2
 
AdRR5 control 10
 
,
 
0.8 0 0
AdCMVPAI-1
(WT hPAI-1)
4 300
 
11 11
 
102 0 0
1,699
 
11
 
2,805
 
11
 
AdPAI-1
 
Q123K
 
(mutated hPAI-1:
defective in VN
binding)
6 106
 
11 1
 
250
 
11 11
 
1,853
 
11
 
6,722
 
11
 
26,840
 
11
 
20,618 0 0
AdPAI-1
 
R346M,M347S
 
(mutated hPAI-1:
defective in PA
inhibition)
5 579 0 0
1,043 0 0
1,426 0 0
1,816 0 0
4,435 0 0
WT None 9 ND
 
11 11
 
None 5 ND
 
111 111
 
Plg
 
2/2
 
None 5 ND
 
1
 
0
None 3 ND
 
11
 
Tumor invasion and angiogenesis were scored as described in Materials and Methods. 
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In all assays, the take rate and growth of transplants were verified by
classical histology and some samples were not taken into account. The
exclusion criteria were the loss of transplantation chamber, the absence
of cells on top of the collagen gel, and the failure of collagen gel adher-
ence onto the host tissue. Based on these parameters, we excluded 
 
z
 
20
and 50% of samples resected from mice untreated or injected with ade-
novirus (see above), respectively. There were no differences in exclusion
rates related to the genotypes of the mice or the type of virus injected.
 
Adenovirus-mediated PAI-1 cDNA Transfer
 
A recombinant adenovirus vector bearing WT human PAI-1 (hPAI-1)
(AdCMVPAI-1 and control adenovirus [AdRR5]) were propagated as
described previously (Gerard and Meidell, 1995; Carmeliet et al., 1997).
Recombinant viruses expressing mutant hPAI-1, AdCMVPAI-1
 
Q123K
 
, and
AdCMVPAI-1
 
R346M,M347S
 
 were generated after substitution of a restriction
fragment containing the desired mutation into the pACCMVPAI-1(WT)
shuttle plasmid (Gerard and Meidell, 1995). PAI-1 with mutation of Gln
123 to Lys had a specific 100-fold decrease in affinity for VN, but retained
full inhibitory activity (Stefansson and Lawrence, 1996). The double point
mutant, Arg 346 to Met and Met 347 to Ser (Shubeita et al., 1990), bound
to VN with the same affinity as WT PAI-1 but did not inhibit PA activity.
We verified that hPAI-1 (WT or mutant forms) interacts efficiently with
murine PA and murine VN according to the procedure described previ-
ously (Vleugels et al., 2000).
1 d after cell transplantation, mice were intravenously injected with 200
 
m
 
l of control or recombinant adenovirus (7 
 
3
 
 10
 
8
 
 pfu). After 5 d, blood
was sampled from the retroorbital sinus and PAI-1 antigen was measured
as described (Bajou et al., 1998). On day 14, mice were killed and trans-
plants were excised and processed as described above. The hPAI-1 cDNA
was used in this study to allow ELISA measurement of circulating PAI-1
levels in all animals, including WT mice.
 
Immunofluorescence and Morphometry
 
Cryostat sections (5 
 
m
 
m thick) were fixed in acetone at 
 
2
 
20
 
8
 
C and in 80%
methanol at 4
 
8
 
C and then incubated with the primary antibodies (Abs).
For double immunofluorescence labeling studies, sections were first incu-
bated for 1 h at room temperature with the two primary Abs: antitype IV
collagen Ab (rabbit polyclonal Ab, diluted 1:100) and antikeratin Ab
(guinea pig polyclonal Ab, diluted 1:20; Sigma-Aldrich). The sections
were washed three times in PBS for 10 min each and subsequently FITC-
or Texas red–conjugated appropriate secondary Abs were applied for 30
min: swine anti–rabbit (diluted 1:40; Dakopat) and/or mouse anti–guinea
pig (diluted 1:40; Sigma-Aldrich). After three washes in PBS for 10 min
each and a final rinse in 10 mM Tris-HCl buffer, pH 8.8, coverslips were
mounted and specific labeling was observed using an inverted microscope
equipped with epifluorescence optics.
Morphometric measurements of cell invasion (average distance of pen-
etration) were performed as described previously (Bajou et al., 1998): mi-
gration 
 
,
 
50 
 
m
 
m was scored as 0; migration from 50 to 150 
 
m
 
m, 
 
1
 
; mi-
gration from 150 to 300 
 
m
 
m, 
 
11
 
; and migration 300 
 
m
 
m, 
 
111
 
.
Morphometric assessment of angiogenesis was scored as follows: vessels
undetected in the collagen gel, 0; vessels infiltrating the collagen without
reaching the malignant epithelial layer, 
 
1
 
; blood vessels in close apposi-
tion to the epithelial layer,
 
 11
 
; and blood vessels intermingling with inva-
sive epithelial tumor sprouts,
 
 111
 
.
 
In Situ Zymography
 
Cryostat sections were coated with a mixture containing 2% skim milk,
0.9% agar, and 600 
 
m
 
g/ml of Plg (Sigma-Aldrich) (Bajou et al., 1998). An
8% milk stock solution was prepared in PBS, heated at 95
 
8
 
C for 30 min,
and centrifuged briefly at 3,000 rpm to remove insoluble material. Slides
were incubated at 37
 
8
 
C in a humidified chamber for 2 h for assessment of
total PA activity and for 24 h in the presence of uPA-specific inhibitor
Figure 1. Invasive behavior
of malignant mouse kerati-
nocytes (PDVA cells), 2 wk
after implantation. In WT
(a), uPA2/2 (b), tPA2/2 (c),
tPA2/2/uPA2/2 (d), and
uPAR2/2 (e) mice, the col-
lagen gel has been remodelled
and malignant cells formed tu-
mor sprouts intermingled with
host tissue. The dotted line
delineates the bottom of the
collagen gel in Plg2/2 (f) and
PAI-12/2 mice (g). Histological
sections were stained with hema-
toxylin and eosin. C, carcinoma
cells; G, collagen gel; H, host
connective tissue. Bar, 100 mm. 
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amiloride (2 mM; Sigma-Aldrich) for assessment of tPA activity. Caseinol-
ysis was monitored by examination under a dark field microscope.
 
Results
 
Plasmin Proteolysis in Tumor Angiogenesis
and Invasion
 
Malignant murine keratinocytes (PDVA cells; Fusenig et
al., 1978) cultured on a collagen gel were implanted onto
the dorsal muscle fascia of WT and transgenic mice. In re-
sponse to angiogenic stimuli (produced by tumor cells;
Skobe et al., 1997), new blood vessels formed in the under-
lying stroma, invaded the collagen gel, and reached the
malignant epithelial layer. Thereafter, the malignant kera-
tinocytes formed tumor sprouts that invaded downwards
into the granulation tissue (Fig. 1 a). Within 2 wk after
transplantation, these tumor islets were intermingled with
closely apposed new vessels. The degree of tumor cell in-
vasion was scored by calculating the average distance
over which the tumor cells infiltrated in the host mesen-
chyme, whereas tumor angiogenesis was semiquantitatively
scored after staining for collagen type IV, a component of
the capillary basement membrane (Fig. 2 a). Compared
with WT mice, tumor angiogenesis (score 
 
111
 
) devel-
oped to a similar degree and invasion of tumor cells oc-
 
curred over a similar distance (
 
.
 
150 
 
m
 
m, 
 
11
 
 or 
 
111
 
) in
uPA
 
2/2
 
, tPA
 
2/2
 
, uPAR
 
2/2
 
 mice, and double tPA
 
2/2
 
/uPA
 
2/2
 
mice (Fig. 1, b–e, and Fig. 2, b–e). Both tumor invasion
and stromal angiogenesis were reduced in Plg
 
2/2
 
 mice (Ta-
ble I, Figs. 1 f and 2 f).
In situ zymography in WT mice revealed that uPA activ-
ity (Fig. 3 a) was mainly localized to the cellular front, con-
taining both invading tumor cells (these malignant kerati-
nocytes are in all experiments WT, and hence produce
uPA and tPA; Bajou et al., 1998) and newly formed blood
vessels, whereas weak tPA activity was largely restricted
to the upper part of the transplant, predominantly consist-
ing of tumor cells (Fig. 3 b). In uPA
 
2/2
 
 mice, tPA activity
was not only restricted to the tumor-rich upper region, but
also expressed at increased levels over the invasion zone,
containing both infiltrating tumor cells and newly formed
vessels (Fig. 3, c and d). These results may suggest a com-
pensatory upregulation of tPA activity in the absence of
uPA. In tPA
 
2/2
 
 mice, caseinolytic activity appeared simi-
lar to that visualized in WT mice and was exclusively me-
diated by uPA (Fig. 3, e and f). The lack of host uPAR in
uPAR
 
2/2
 
 mice did not influence the intensity or the local-
ization of uPA-mediated lysis (Fig. 3, g and h). These data
indicate that formation of host-derived stromal vessels re-
quires plasmin, normally generated by uPA. However, the
two PAs may be somehow redundant.
Figure 2. Immunofluorescence
labeling of malignant kerati-
nocytes and vessels 2 wk after
implantation. PDVA cells were
transplanted into WT (a),
uPA2/2 (b), tPA2/2 (c), tPA/
uPA2/2 (d), uPAR2/2 (e),
Plg2/2 (f), and PAI-12/2 (g)
mice. Malignant cells were de-
tected on cryostat sections by
using antikeratin Ab (green)
and vessels were detected us-
ing an anticollagen type IV Ab
(red). At all times after graft-
ing, collagen type IV labelings
were codistributed with endo-
thelial cells recognized by the
anti–mouse platelet endothe-
lial cell adhesion molecule immunostaining (data not shown). The dotted line delineates the bottom of the collagen gel, revealing not
only a reduced upward migration of vessels in Plg2/2 mice (e), but also that vessels remained confined beneath the collagen gel in PAI-
12/2 mice (f). C, carcinoma cells; G, collagen gel; H, host connective tissue. Bar, 100 mm. 
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Normal Tumor Angiogenesis and Invasion in
VN
 
2/2
 
 Mice
 
In agreement with our previous findings, host-derived ves-
sels in PAI-1
 
2/2
 
 mice were unable to migrate towards the
tumor cells and remained confined beneath the collagen
gel (Table I, Fig. 2 g). In addition, malignant cells failed to
invade the host tissue in PAI-1
 
2/2
 
 mice (the average depth
of invasion was 
 
,
 
50 
 
m
 
m, scored 0) and remained as an ir-
regular stratified epithelium on top of the collagen gel (Fig.
1 f). Since PAI-1 binds strongly to VN and alters the adhe-
sion and migration of cells on this matrix substrate, we an-
ticipated that lack of VN should mimic the impaired tumor
angiogenesis and invasion phenotype of PAI-1
 
2/2
 
 mice.
However, transplantation of malignant keratinocytes into
VN
 
2/2
 
 mice was associated with normal, and perhaps even
accelerated angiogenesis and tumor infiltration (Fig. 4).
 
Mechanism of the Tumor-promoting Role of PAI-1
We had demonstrated previously that tumor vasculariza-
tion and invasion in PAI-12/2 mice can be restored by in-
travenous injection of a recombinant adenovirus express-
ing human PAI-1 (AdPAI-1; Bajou et al., 1998). To
further investigate whether the role of PAI-1 in promoting
tumor invasion and angiogenesis depended on its ability to
block proteolytic activity, or instead on its ability to bind
to VN, two additional adenovirus constructs were pro-
duced that expressed a mutant form of hPAI-1 that: (a)
exhibited normal binding to VN but was inactive in inhib-
iting the proteolytic activity of tPA and uPA (AdPAI-
1R346M, M347S), or (b) inhibited the PA activity normally but
had a dramatically reduced affinity for VN (AdPAI-
1Q123K). Intravenous injection of these adenoviruses re-
sulted in 100–1,000-fold increased plasma levels of hPAI-1
Figure 3. In situ zymography of
PDVA cells 2 wk after transplantation
into WT (a and b), uPA2/2 (c and d),
tPA2/2 (e and f), and uPAR2/2 (g and
h) mice. Total PA activity was visual-
ized as a dark zone of lysis (dark field
images) after incubation for 6 h (a, c, e,
and g). In the presence of 2 mM
amiloride for 36 h, only tPA activity
was detected (b, d, f, and h). C, carci-
noma cells; H, host connective tissue.
Bar, 1 mm.The Journal of Cell Biology, Volume 152, 2001 782
above normal murine PAI-1 plasma levels of WT mice (2
ng/ml; Table I). Injection of the AdPAI-1Q123K virus into
PAI-12/2 hosts restored tumor vascularization and inva-
sion in five of six mice (Table I). In sharp contrast, injec-
tion of the AdPAI-1R346M, M347S virus into PAI-12/2 hosts
was unable to restore tumor vascularization and invasion
in any of the six mice (Table I). Thus, the requirement for
PAI-1 in tumor angiogenesis and invasion, in this model,
appears not to be due to inhibition of cellular adhesion
through its interaction with VN, but rather due to preven-
tion of excessive plasmin formation.
Discussion
Proteolytic breakdown of extracellular matrices by uPA/
plasmin has been associated with tumor invasion and an-
giogenesis (Andreasen et al., 1997; Stephens et al., 1999).
However, prognostic studies have indicated that the pro-
tease inhibitor PAI-1 is a clinical marker of poor prognosis
in a variety of human cancers (Pedersen et al., 1994a,b;
Brunner et al., 2000). The molecular mechanisms of action
that underlie this apparent paradox remained to date un-
explained. Nonetheless, a fundamental understanding of
these processes is mandatory because of the growing inter-
est to develop uPA antagonists as angiogenesis inhibitors.
This study demonstrates that plasmin proteolysis is in-
volved in tumor angiogenesis but, at the same time, indi-
cates that an excessive plasmin formation, as a result of
PAI-1 deficiency, prevents normal assembly and out-
growth of newly formed stromal vessels. This explanation
of the observed clinical paradox is supported by the exper-
iment using mutated PAI-1 constructs and showing that
PAI-1 mediates its proangiogenic effect, not by its interac-
tion with VN but rather by its antiprotease function.
The Plg/plasmin system has been implicated in extracel-
lular proteolysis during angiogenesis (Montesano et al.,
1990). However, studies in gene-inactivated mice have re-
vealed that angiogenesis during embryonic development
occurs normally in the absence of both PAs and Plg and
that angiogenesis during pathological conditions can occur
to a large degree in the absence of either Plg, tPA, or uPA,
possibly by redundancy or compensation by other protein-
ases (Bugge et al., 1997, 1998; Carmeliet and Collen, 1999;
Lund et al., 1999). In accordance with these observations,
the present findings show that tumor vascularization was
not affected in mice deficient in tPA, uPA, or uPAR. No-
tably, stromal/host lack of uPA may in the present tumor
model have been compensated by upregulation of tPA ac-
tivity. However, in the absence of PA in combined defi-
cient tPA2/2/uPA2/2 mice, the invasive and angiogenic
phenotype of malignant keratinocytes was similar to that
observed in WT mice or mice with single deficiencies
(uPA2/2 or tPA2/2 mice). Interestingly, both Plg and ac-
tive plasmin were detected by Western blotting in the in-
vasive region of tumors transplanted onto WT and double
tPA2/2/uPA2/2 mice (data not shown). These observa-
tions suggest that in vivo neither tPA nor uPA, produced
by host cells individually or in combination, is essential for
Plg activation; and other enzyme(s) can compensate the
lack of uPA and tPA. Alternatively, the presence of active
plasmin might result from activation by uPA or tPA pro-
duced by cancer cells (Bajou et al., 1998). The Plg activa-
tion pathway(s) occurring in the double-deficient mice
remain(s) to be determined, but might involve blood co-
agulation factor XII, kininogen, or kalikrein (Colman,
1969; Miles et al., 1983; Carmeliet et al., 1994). The re-
duced tumor vascularization and invasion in Plg2/2 mice
indicate that plasmin is required for optimal tumor pro-
gression. The fact that some tumor angiogenesis was ob-
served in these mice suggests that other enzymes may, at
least in part, contribute to the angiogenic phenotype.
There are several mechanisms whereby PAI-1 could ex-
ert its proangiogenic activity. First, PAI-1 is known to in-
teract with VN and, consequently, has been considered as
a molecular switch governing uPAR- and/or integrin-
mediated cell adhesion and motility (Deng et al., 1996;
Chapman, 1997). Binding of PAI-1 to VN blocks the inter-
action between integrins and the uPAR–uPA complex
with VN, thereby inhibiting cell adhesion and migration
(Loskutoff et al., 1999). However, in our transplantation
model, the facilitating effects of PAI-1 on angiogenesis
and invasion are not dependent on its interaction with VN.
Indeed, neither tumor vascularization nor invasion were
restored by injection of an adenovirus expressing a mutant
PAI-1 that binds normally to VN but is inactive as a PA in-
hibitor. Similarly, deficiency of VN in mice did not sup-
press the typical malignant keratinocyte invasion and tu-
mor vascularization. Second, PAI-1 may affect endothelial
cell migration via its competition with uPAR for VN bind-
ing. PAI-1 may potentiate tumor cell migration by stimu-
lating internalization of uPA–uPAR complexes (Conese
and Blasi, 1995). When uPAR is recycled at the cell sur-
face, it can facilitate successive rounds of adhesion as the
endothelial cells move along their substrates. However,
this hypothesis is unlikely in the presented model, since tu-
mor vascularization and invasion were not affected in
uPAR2/2 mice. Third, PAI-1 may prevent production of
the angiogenesis inhibitor angiostatin that can be cleaved
from Plg by plasmin (O’Reilly, 1997). However, lack of Plg
was associated with a decreased, rather than an increased,
formation of blood vessels, suggesting that in this model,
Figure 4. Invasive behavior of malignant mouse keratinocytes
(PDVA cells) 2 wk after implantation into WT mice (a) or Vn2/2
mice (b). Histological sections stained with hematoxylin and
eosin revealed tumor cells (C) intermingled with host cells (H) in
both WT mice (a) and Vn2/2 mice (b). Bar, 100 mm.Bajou et al. PAI-1 Angiogenic Effect by Antiproteolytic Activity 783
angiostatin generation is not a critical event. This is in ac-
cordance with findings on other tumor models in Plg-defi-
cient mice (Bugge et al., 1997, 1998). Fourth, PAI-1 may
be implicated in inhibiting the proteolytic activity of both
PAs, thereby reducing overall plasmin formation. This
possibility is supported by the restoration of tumor angio-
genesis in PAI-1–deficient mice after adenovirus-medi-
ated transfer of a mutant PAI-1, defective in binding to
VN but able to inhibit PA-activity. Presumably, increased
plasmin proteolysis in PAI-1–deficient mice may prevent
accumulation of fibrin, fibronectin, laminin, and, indirectly
via activation of other matrix degrading proteinases, of ad-
ditional extracellular matrix components that are known
to stimulate endothelial proliferation and outgrowth. By
mediating deposition of such a scaffold, PAI-1 also would
allow newly formed vessels to acquire the necessary stabil-
ity and maturity. Excessive degradation of extracellular
matrix is incompatible with efficient cellular migration
(Montesano et al., 1990; Pepper and Montesano, 1990).
The maintenance of a certain degree of extracellular ma-
trix integrity is indeed an essential requirement for capil-
lary morphogenesis. PAI-1 may thus balance PA-medi-
ated pericellular proteolysis, protecting the stroma from
excessive proteolysis during endothelial cell invasion.
In conclusion, our data indicate that in vivo, like previ-
ously shown in vitro (Pepper and Montesano, 1990; Liu et
al., 1995), a critical balance between proteases and PAI-1
is necessary for optimal invasion. However, in contrast to
in vitro data, lack of VN, uPAR, uPA, tPA, or both uPA
and tPA did not impair tumor formation. This discrepancy
between in vitro and in vivo data probably indicates that
compensatory mechanisms are active in vivo but not in
vitro. Our observations demonstrate that PAI-1 is essen-
tial for tumor angiogenesis, not via its interaction with VN
but rather via counterbalancing excessive plasmin genera-
tion. Our findings also warrant against the uncontrolled
use of inhibitors of proteinases (such as of uPA and per-
haps also of metalloproteinases) for suppression of tumor
angiogenesis. They also indicate that neutralization of
PAI-1 activity may be an effective new therapeutic ap-
proach for suppression of tumor angiogenesis.
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